The Life Sciences IPOs + Capital Markets team advised Kymera Therapeutics, Inc. (NASDAQ: KYMR) on its upsized initial public offering of 8,684,800 common shares at a public offering price of $20.00 per share. All of the shares are being offered by Kymera. The gross proceeds of the offering, before deducting underwriting discounts and commissions, and other offering expenses payable by Kymera, are expected to be approximately $173.7 million. Kymera has granted the underwriters a 30-day option to purchase up to an additional 1,302,720 common shares at the initial public offering price.

Kymera Therapeutics is a biopharmaceutical company focused on advancing the field of targeted protein degradation by accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Goodwin has advised Kymera since inception and represented the company in its Series A, B and C financings, as well as its collaborations with Vertex Pharmaceuticals and Sanofi.

The Goodwin team was led by Bill Collins, Sarah Ashfaq and Gabriela Morales-Rivera, and included Katherine Maxwell, Kristen Armstrong, Janet Andolina,Alex Denniston, Morgan Frisoli, Jennifer Fay, Caroline Galiatsos, Roger Cohen, and Nikhil Sethi.

For additional information, please read the press release and articles in Boston Business Journal and Endpoints News.